Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Virginia Commonwealth University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
University of California, San Francisco
St. Jude Children's Research Hospital
Deciphera Pharmaceuticals, LLC
Assistance Publique - Hôpitaux de Paris
University College, London
Virginia Commonwealth University
AbbVie
University of Pittsburgh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Case Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Children's Oncology Group
INSYS Therapeutics Inc
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center